Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. The financing will scale manufacturing, accelerate commercial deployment

Additional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinic

MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies across the commercialization finish line. Earlier this year, MeiraGTx bought back botaretigene sparoparvovec (bota-vec) from Johnson & Johnson, despite the therapy failing to improve vision-guided mobility in patients with X-linked retinitis pigmentosa (XLRP) in a phase 3 trial . Despite the trial miss, the company touted “clinically meaningful benefit” seen in the data and s

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones July 07, 2026 --- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchas

July 7, 2026 -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-h

Financing brings together a syndicate of top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and Celea founder PureTech Health, alongside a large, US-based healthcare-focused fund and a leading sovereign wealth fund Proceeds will enable early Q3 2026 initiation of SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone vs. pirfenidone Celea Therapeutics ("Celea" or the "Company"), a clinical-stage biopharmaceutical company d

PureTech launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling PureTech’s transition to a lean operating model PureTech retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care Pure

Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology July 1, 2026 -- ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will su

The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew. Ipsen will absorb California-based Kartos Therapeutics in a back-heavy agreement that will give the French biotech a late-stage drug candidate for a rare blood cancer. The deal involves a $450 million upfront payment from Ipsen, according to a news release on Monday morning. The co

Imagion Biosystems, Ltd. (ASX: IBX) announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA’s clearance of the company’s IND application for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the MagSense® imaging agent in HER2+ breast cancer. The company has already begun trial activation activities and expects to begin patient recruitment later this year. “We are very pleased with the strong demand we saw fro